Following last week’s announcement of our new Chief Executive Officer, Santero Therapeutics continues to strengthen its execution-focused leadership team with the appointment of Cuong Vuong, PhD, as Chief Scientific Officer (CSO).
Cuong brings deep scientific expertise and a proven track record in advancing innovative antibacterial programs and driving strategic R&D execution. He joins Santero Therapeutics following senior leadership roles at Selmod GmbH, Janssen Pharmaceuticals (Johnson & Johnson Innovative Medicine), and AiCuris Anti-infective Cures AG. His deep experience and proven leadership will be critical as we sharpen our scientific focus, accelerate program execution, and create long-term value.
With a reinforced executive team in place, Santero Therapeutics is entering a phase of increased momentum, focused execution, and scalable growth. This strengthened leadership positions the company to deliver on key upcoming milestones and to build a sustainable, science-driven organization.
We are delighted to welcome Cuong as we move forward into this next chapter.
👉 Stay tuned as we continue to build.